Drug Database
AN

anti-H5N1 avian influenza antibodies (Fabenflu / FBF001)

✓ Approved

Fab'entech · 多克隆抗体 · 多克隆抗体

什么是 anti-H5N1 avian influenza antibodies?

anti-H5N1 avian influenza antibodies 是一种多克隆抗体,由Fab'entech研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Fabenflu, FBF001
公司Fab'entech
药物类别多克隆抗体, 抗体
给药途径Injectable (Others), Intravenous (IV)
状态Approved

治疗适应症

anti-H5N1 avian influenza antibodies 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsInfluenza✓ Approved

相关研究文献

PubMedEmerging infectious diseases2026-11-19

Serologic Evidence of Avian Influenza Virus Exposure in Livestock, Egypt, 2024-2026.

Gomaa Mokhtar M, El-Shesheny Rabeh R, El Taweel Ahmed A, Kutkat Omnia O et al.

Spillover of influenza A(H5N1) virus to cattle in the United States sparked global concern. We investigated whether endemic avian influenza viruses are potentially spilling over into domestic livestock in Egypt. We detected influenza H9N2 antibodies in 2.5% and H5N1 antibodies in 2.9%-4.5% of tested animals. Additional surveillance will elucidate host infection dynamics.

PMID 43052695
阅读全文 →
PubMedEmerging infectious diseases2026-11-19

Cross-Protection against Influenza A(H5) Clade 2.3.4.4b Viruses after A(H1N1)pdm09 Infection.

Sun Xiangjie X, Belser Jessica A JA, Li Zhu-Nan ZN, Brock Nicole N et al.

We challenged ferrets previously infected with influenza A(H1N1)pdm09 virus with H5N1 or H5N5 clade 2.3.4.4b viruses to assess cross-protection. Results show that previous A(H1N1)pdm09 virus immunity conferred partial protection against both viruses, with slightly reduced protection against H5N5 compared with H5N1, potentially reflecting the absence of cross-reactive N5 neuraminidase antibodies.

PMID 43053314
阅读全文 →
PubMedNPJ vaccines2026-11-19

Maternal influenza vaccination boosts durable breast milk antibody-mediated protection in infants.

Wessel Remziye E RE, Tong Xin X, Bhattacharya Allison A, Burrell Allison R AR et al.

Influenza contributes to significant disease burden worldwide, and young infants are at an increased risk of severe influenza infection. Maternal antibodies transferred across the placenta and through breast milk confer anti-influenza immunity to the newborn. Placental transfer provides a finite window of protection, but breast milk antibody transfer may provide prolonged immunity across the postnatal period. Yet, how breastmilk antibody profiles are shaped by maternal vaccination, change postnatally, and whether they contribute to protection against influenza remains incompletely defined. Comprehensive systems serological analysis of influenza-specific antibodies across 21 different antigens in a longitudinal birth cohort revealed maternal influenza vaccination was associated with enhanced antibody-dependent complement deposition (ADCD) and FcγR binding in breast milk at two weeks postpartum. This effect was further stratified by trimester of vaccination: first trimester vaccinees exhibited increased ADCD and IgM levels, whereas second or third trimester vaccination was associated with increased FcγR and FcαR binding. Analysis of longitudinal samples revealed that anti-influenza antibody responses in milk shift postpartum toward increased FcγR binding and decreased ADCD activity and IgM levels. Finally, baseline ADCD activity in breast milk and serum IgG1 levels were identified as signatures of resistance to influenza infection during the first six months of life. A multivariate model combining correlates of protection across milk and serum compartments offered greater predictive power compared to either compartment alone, suggesting both routes of antibody transfer bolster anti-influenza immunity in infants. These data collectively suggest that maternal influenza vaccination confers infant protection via breast milk to augment placental antibody transfer, and the functional capacity of these protective antibodies could be enhanced with prolonged breastfeeding.

PMID 43052358
阅读全文 →
PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-11-19

Anatomical Compartmentalization in Chickens Drives Divergent H9N2 Influenza Evolution Toward Human Receptor Binding and Immune Escape.

Chen Wei W, Zhang Lingkai L, Pei Xinyi X, Guo Chaoxuan C et al.

Avian influenza A(H9N2) viruses pose a pandemic threat, having acquired preferential binding to human receptors and the ability to evade immunity in chickens. However, the selective forces driving these traits remain unclear. Here, we show how anatomical compartmentalization within chickens shapes hemagglutinin (HA) evolution. Using deep mutational scanning coupled with in vivo studies, we find that pre-existing immunity reduces viral load and blocks transmission, thereby imposing strong selection on viral diversity. Distinct tissues exert divergent selection pressures in immunized chickens. The upper respiratory tract mainly enriches viruses with high-affinity binding to human-type receptors, whereas the lower respiratory tract preferentially favors antibody-escape viruses. This functional difference was validated using variants carrying defined substitutions, which showed fitness aligned with their respective compartment. Our results demonstrate that tissue-specific selection within an avian host can concurrently shape viral diversity toward human adaptation and immune evasion, providing a mechanism for the emergence of variants with pandemic potential in poultry.

PMID 43052218
阅读全文 →
PubMedAJE advances : research in epidemiology2026-11-19

Assessing the broader impact of influenza: a meta-analysis of cause-specific and all-cause influenza-associated mortality.

Wong Jessica Y JY, Cheung Justin K JK, Wu Jiaxin S JS, Choi Sammi S et al.

The mortality impact of influenza epidemics is often quantified via increases in respiratory mortality, but this may not fully capture other health outcomes like cardiovascular events. We aimed to explore the ratios of influenza-associated cause-specific to all-cause mortality. We reviewed relevant articles from PubMed and EMBASE which reported both influenza-associated all-cause mortality and at least 1 death grouping: pneumonia and influenza (P&I), respiratory, or respiratory plus cardiovascular (R + C) diseases. Only population-based estimates from influenza seasons were included. We included 130 mortality ratio estimates from 54 studies. We identified substantial heterogeneity in estimates (0.012-0.93). Higher ratio estimates were attributed to R + C diseases (0.45-0.93) compared with respiratory diseases (0.078-0.66) or P&I (0.012-0.38). Respiratory mortality to all-cause mortality ratios increased substantially with age. Our review quantifies the broader mortality burden of influenza, with substantial impact associated with cardiovascular deaths in addition to influenza-associated respiratory deaths.

PMID 43053809
阅读全文 →
PubMedThe Medical journal of Australia2026-11-19

Influenza A(H3N2) Subclade K Activity in Australia in 2025: Epidemiology and Vaccine Effectiveness Results From General Practice Sentinel Surveillance.

Chilver Monique B N MBN, Sullivan Sheena G SG, Selway Caitlin A CA, Miller Jessica E JE et al.

To describe the epidemiology, clinical characteristics, vaccine effectiveness (VE), antiviral prescribing and virological properties for influenza A(H3N2) subclade K detected through Australian general practice sentinel surveillance in 2025. Retrospective, observational study using routinely collected general practice surveillance data; VE was estimated using a test-negative design. Data were collected from sentinel general practice sites participating in Australian Sentinel Practices Research Network surveillance across Australia during International Organization for Standardization weeks 1-52 of 2025. Patients presenting with influenza-like illness were systematically selected for virological sampling. Demographic and clinical characteristics of patients with laboratory-confirmed influenza; VE against general practice-attended, laboratory-confirmed influenza; antiviral prescribing; and sequence-based markers of reduced antiviral susceptibility. Among 3185 patients with influenza-like illness who were swabbed, 666 (21%) tested positive for influenza. Influenza A(H3N2) subclade K was first detected in week 34 of 2025 and circulated beyond the typical influenza season, peaking in November-December. Of 98 subclade K detections, 36 (37%) were in children aged 5-17 years. Compared with other types, subtypes or subclades of influenza, clinical presentations of subclade K cases were broadly similar, with no consistent clinical pattern distinguishing subclade K. VE against subclade K was 50% overall (95% confidence interval, 8.9-73) and 76% among persons aged 9 months to 17 years (95% confidence interval, 18-93). Among all patients with a recorded antiviral prescription, two-thirds were within the recommended 48-h symptom onset window (76/114). No subclade K viruses had mutations known to reduce susceptibility to the influenza antivirals assessed, including oseltamivir. Among patients attending Australian sentinel general practices in 2025, subclade K prolonged influenza activity into the summer months. General practice sentinel surveillance of influenza can provide timely information on emerging variants and changes in the timing of influenza circulation, raising clinical awareness outside the usual season, informing vaccination strategies and prompting assessment for antiviral treatment.

PMID 43053545
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多anti-H5N1 avian influenza antibodies